Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Carmat    ALCAR   FR0010907956

CARMAT

(ALCAR)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

CARMAT : to Present the Positive Interim Results of the First Part of the PIVOTAL Study at the 39th ISHLT Annual Meeting in Orlando, Florida

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/28/2019 | 01:01am EDT

To date, the CARMAT total artificial heart has achieved a record 13 months of continuous individual support within the framework of the study

Regulatory News:

CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced its participation to the 39th annual meeting of the ISHLT – International Society for Heart & Lung Transplantation, one of the world’s largest forums in this field, which will take place in Orlando, Florida, from April 3 to 6, 2019.

At this event, Dr. Piet Jansen, Medical Director of CARMAT, will present the positive interim results of the first part of the PIVOTAL study, published last January, during the “Advances in Short- and Long-Term Mechanical Circulatory Support - What’s Next?” symposium.

The ISHLT annual meeting is an excellent platform to share the clinical results of the first cohort of 10 patients included in the PIVOTAL study with international cardiology experts. Our previous publication in the Journal of Heart and Lung Transplantation, the official journal of the ISHLT, which focused on data from our feasibility study, generated much enthusiasm, and we are delighted to be able to provide new clinical elements to further support, with more hindsight, the potential benefits of the CARMAT TAH for treating patients suffering from end-stage biventricular heart failure. To date, we are pleased to announce that our prosthesis has achieved, within the framework of the PIVOTAL study, a record 13 months of individual support, and 5 years 10 months of cumulative support in the 11 implanted patients”, said Dr. Piet Jansen, Medical Director of CARMAT.

Pr. Ivan Netuka, Professor of Cardiac Surgery and Chairman of the Department of Cardiovascular Surgery, IKEM, Prague, Czech Republic and Principal Investigator of the second cohort of the PIVOTAL study, commented: the support experience exceeding one year in our patient provides him an enjoyable life at his home environment and offers a viable therapeutic alternative for patients not eligible to receive a donor heart”.

Information on the Session:
Symposium: Advances in Short- and Long-Term Mechanical Circulatory Support - What’s Next?
Session: The Future of Total Heart Replacement – CARMAT Perspective
Date: Thursday April 4, 2019
Time: 4:55 – 5:15 pm
Location: Loews Meeting Complex, Grand Caribbean 1-7

●●●

Name: CARMAT
ISIN code: FR0010907956
Ticker: ALCAR

●●●

DISCLAIMER
This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT ("the Company") in any country. This press release contains forward‐looking statements that relate to the Company’s objectives. Such forward‐looking statements are based solely on the current expectations and assumptions of the Company’s management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. The Company’s objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties.

No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Document de Référence registration document filed with the Autorité des Marchés Financiers under number D.19-0135 on March 12, 2019, as well as changes in economic conditions, the financial markets or the markets in which CARMAT operates. In particular, no guarantee can be given concerning the Company’s ability to finalize the development, validation and industrialization of the prosthesis and the equipment required for its use, to manufacture the prostheses, satisfy the requirements of the ANSM, enroll patients, obtain satisfactory clinical results, perform the clinical trials and tests required for CE marking and to obtain the CE mark. CARMAT products are currently exclusively used within the framework of clinical trials.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARMAT
07/04CARMAT : has Presented Additional Interim Results of the PIVOTAL Study at the AS..
BU
05/21CARMAT : Announces the Resumption of Production of Prostheses for the PIVOTAL St..
BU
04/12CARMAT : Announces a Delay in the Resumption of Production of Prostheses for the..
AQ
04/10CARMAT : Announces a Delay in the Resumption of Production of Prostheses for the..
BU
03/29CARMAT : the Shareholders' Meeting approves all of the resolutions supported by ..
BU
03/28CARMAT : to Present the Positive Interim Results of the First Part of the PIVOTA..
BU
02/13CARMAT : Reports Its 2018 Annual Results and Confirms Its 2019 Development Prosp..
BU
01/21CARMAT : 2019 Financial Calendar
BU
01/16CARMAT : presents positive interim results of the first part of its PIVOTAL stud..
AQ
01/15CARMAT : presents positive interim results of the first part of its PIVOTAL stud..
BU
More news
Financials (EUR)
Sales 2019 -
EBIT 2019 -42,8 M
Net income 2019 -42,4 M
Finance 2019 0,63 M
Yield 2019 -
P/E ratio 2019 -3,94x
P/E ratio 2020 -3,60x
EV / Sales2019 infx
EV / Sales2020 infx
Capitalization 187 M
Chart CARMAT
Duration : Period :
Carmat Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARMAT
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 25,15  €
Last Close Price 19,88  €
Spread / Highest target 27,3%
Spread / Average Target 26,5%
Spread / Lowest Target 25,8%
EPS Revisions
Managers
NameTitle
Stéphane Piat Chief Executive Officer & Director
Jean-Pierre Garnier Chairman
Pascale d’Arbonneau Chief Financial & Administrative Officer
Marc Grimmé Director-Research & Development
Piet Jansen Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CARMAT-15.40%208
STRYKER CORPORATION36.59%79 882
SMITH & NEPHEW32.04%20 705
WRIGHT MEDICAL GROUP NV-19.76%2 767
GLAUKOS CORP4.29%2 158
INSPIRE MEDICAL SYSTEMS INC51.53%1 531